Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan
Zacks Investment Research | Jan 12, 2020 10:03PM ET
Hologic Inc. (NASDAQ:HOLX) recently announced preliminary revenue results for first-quarter fiscal 2020. The company is slated to release its detailed financial results for the period on Jan 29.
Hologic projects an impressive performance for the fiscal first quarter, expecting to exceed its own estimates on the revenue front. However, this fails to impact the stock price which dipped 0.2% to reach $53.17 at Jan 10’s close.
In the to-be-reported quarter, Hologic expects total revenues to inch up 2.4% (up 2.8% at constant exchange rate or CER) on a year-over-year basis to $850.5 million, ahead of the current Zacks Consensus Estimate of $844.03 million. This also marginally exceeds the upper limit of the company's earlier provided revenue guidance of $835-$850 million.
Excluding Acquisitions and Divestitures, revenues are predicted to increase 4.1% (up 4.6% at CER).
According to the company, in the fiscal first quarter, revenues were strong within Surgical and Diagnostics. However, this was more than offset by weakness in the divested Medical Aesthetics business.
Diagnostics (36.6% of total revenues) is likely to rise 5.5% at CER to $311.5 million. Breast Health (38.9%) is estimated to grow 2.4% on a year-over-year basis to $331.1 million. GYN Surgical (14%) revenues are envisioned to ascend 10.2% on a year-over-year basis to $119.1 million. Skeletal Health (2.8%) is anticipated to improve 11.4% year over year to $23.5 million. However, Medical Aesthetics is forecast to decline 17.7% at CER to touch $65.3 million in the quarter to be reported.
Per the company’s last-updated outlook, adjusted EPS is assumed to be 59-61 cents for first-quarter fiscal 2020.
Share Repurchase Update
The board of directors recently approved a new $500-million worth share repurchase authorization effective third-quarter fiscal 2020 following the expiration of the company’s existing buyback plan.
Share Price Movement
Hologic has underperformed its Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.